Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryCRO

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1500935

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1500935

Drug Discovery Outsourcing

PUBLISHED:
PAGES: 89 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Drug Discovery Outsourcing Market to Reach $6.6 Billion by 2030

The global market for Drug Discovery Outsourcing estimated at US$4.3 Billion in the year 2023, is expected to reach US$6.6 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Lead Identification & Candidate Optimization Workflow, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$3 Billion by the end of the analysis period. Growth in the Preclinical Development Workflow segment is estimated at 5.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 10.2% CAGR

The Drug Discovery Outsourcing market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 5.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$945.5 Million by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 33 Featured) -

  • Albany Molecular Research, Inc.
  • Aptuit LLC
  • Charles River
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Domainex
  • EVOTEC
  • GenScript
  • Jubilant Biosys
  • LabCorp
  • Merck & Co., Inc.
  • Oncodesign
  • PPD, Inc.
  • QIAGEN
  • QuintilesIMS
  • Selcia Ltd.
  • Sigma-Aldrich Co. LLC
  • TGS Lifesciences Pvt Ltd.
  • Thermo Fisher Scientific, Inc.
  • Viva Biotech Ltd.
  • WIL Research
  • WuXi AppTec
Show more
Product Code: MCP21667

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Drug Discovery Outsourcing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Drug Discovery Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Drug Discovery Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Lead Identification & Candidate Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Lead Identification & Candidate Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Lead Identification & Candidate Optimization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Preclinical Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Preclinical Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Preclinical Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Target Validation & Functional Informatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Target Validation & Functional Informatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Target Validation & Functional Informatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Target Identification & Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Target Identification & Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Target Identification & Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Workflows by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Workflows by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Workflows by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Endocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Gastrointestinal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Anti-Infective by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Anti-Infective by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Respiratory System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Respiratory System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Respiratory System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Pain & Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Pain & Anesthesia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 42: World 16-Year Perspective for Pain & Anesthesia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 45: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 48: World 16-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 49: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 50: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 51: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 52: World Recent Past, Current & Future Analysis for Large Molecules (Biopharmaceuticals) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: World Historic Review for Large Molecules (Biopharmaceuticals) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: World 16-Year Perspective for Large Molecules (Biopharmaceuticals) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 55: World Drug Discovery Outsourcing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • JAPAN
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • CHINA
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: China 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: China 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • EUROPE
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Drug Discovery Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Drug Discovery Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • FRANCE
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: France 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: France 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: France 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • GERMANY
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Drug Discovery Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • INDIA
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: India 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: India 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: India 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Drug Discovery Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Drug Discovery Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Drug Discovery Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Drug Discovery Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030
  • AFRICA
    • Drug Discovery Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Drug Discovery Outsourcing by Workflow - Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Drug Discovery Outsourcing by Workflow - Percentage Breakdown of Value Sales for Lead Identification & Candidate Optimization, Preclinical Development, Target Validation & Functional Informatics, Target Identification & Screening and Other Workflows for the Years 2014, 2024 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Drug Discovery Outsourcing by Therapeutic Area - Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Drug Discovery Outsourcing by Therapeutic Area - Percentage Breakdown of Value Sales for Hematology, Cardiovascular, Endocrine, Gastrointestinal, Anti-Infective, Other Therapeutic Areas, Respiratory System, Pain & Anesthesia, Oncology and Ophthalmology for the Years 2014, 2024 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Drug Discovery Outsourcing by Drug Type - Small Molecules and Large Molecules (Biopharmaceuticals) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Drug Discovery Outsourcing by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules (Biopharmaceuticals) for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!